Pivot Bio
Pivot Bio is an agtech company developing patented crop nutrition technologies that provide nitrogen to crops like corn and wheat.
Secondary Market Price
Secondary Market Price
How Pivot Bio Measures Up
To help you manage your Pivot Bio equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series E
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Pivot Bio's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Pivot Bio Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Pivot Bio's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Pivot Bio is an agricultural technology company that develops biological crop nutrition products. The company's main focus is creating alternatives to synthetic nitrogen fertilizers by using microbes that provide nitrogen to crops. Its products are available for corn, corn silage, wheat, sorghum, and other small grains. Founded in 2011 by co-founder Karsten Temme and headquartered in Berkeley, California, the company has grown from a scientific concept to a commercial operation serving millions of acres. Pivot Bio has raised a total of $616.8 million in funding, which includes a Series D round of $430 million in August 2021.
The company is currently focused on global expansion and product line diversification. It is awaiting final regulatory approval to make its technology commercially available in Brazil and is expanding its solutions to Africa through a partnership with MIT. In the past year, Pivot Bio launched four new products, including its third-generation nitrogen technology for corn and its first products for sorghum and cotton. The company reported achieving $100 million in revenue in 2023 and has recently added new leaders to its senior management and commercial teams to support its growth.
- Breakthrough Energy Ventures
- Temasek
- DCVC
- Prelude Ventures
- Spruce Capital Partners
- Codon Capital
- Bunge Ventures
- Continental Grain Company
- Tekfen Ventures
- Pavilion Capital
- Generation Investment Management
- G2 Venture Partners
- Rockefeller Capital Management
- Alan Cohen
- Roger Underwood
- Co-Founder, Karsten Temme
- Co-Founder, Alvin Tamsir
- Co-Founder, Christopher Voigt
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Pivot Bio worth joining?
Deciding to join a company like Pivot Bio depends on your personal career goals and financial situation. Tools like Prospect can help you understand the potential value of your equity compensation to make a more informed decision.
What should I do with my Pivot Bio stock?
Managing pre-IPO stock involves complex decisions around taxes, timing, and diversification. Using a platform like Prospect can help you create a personalized strategy for your Pivot Bio equity based on your financial goals.
Can you sell Pivot Bio stock?
As Pivot Bio is a private company, you can typically sell shares through secondary markets or during company-approved tender offers. Platforms like Prospect offer tools to help navigate these sales and determine which shares are most tax-optimal to sell.
How can I find the value of my Pivot Bio stock?
The official value is determined by the company's 409A valuation, but this doesn't reflect market price or future potential. To better understand what your shares could be worth, you can use predictive modeling tools like those offered by Prospect, which forecast value based on proprietary data.
What is Pivot Bio's equity worth?
The worth of Pivot Bio's equity is tied to the company's overall private valuation, which fluctuates with funding rounds and business performance. For a personalized analysis of what your specific equity holdings could be worth, a platform like Prospect can model various financial scenarios and potential outcomes.
What is Pivot Bio's stock ticker symbol?
Since Pivot Bio is a private company, it is not listed on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are only assigned to companies once they complete an Initial Public Offering (IPO).
Can I buy or sell Pivot Bio stock?
Selling private stock like Pivot Bio's is possible through secondary markets or tender offers, though restrictions may apply. Buying shares is generally limited to accredited investors or employees participating in equity programs.
What is the criteria to buy or invest in Pivot Bio stock?
Investing in a private company like Pivot Bio is typically restricted to accredited investors who meet specific income or net worth requirements set by financial regulators. Employees, however, can acquire equity through their compensation packages without needing to meet these criteria.
